ArticlePloS one2012
Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO).
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.Genome medicine · 2019Pooled it
- Advancing the bioassay ontology through integrated PK/PD and safety pharmacology representation.Journal of biomedical semantics · 2026Article
- Modeling structure-activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics.Frontiers in endocrinology · 2023Article
- MolData, a molecular benchmark for disease and target based machine learning.Journal of cheminformatics · 2022Article
- The Life of a Trailing Spouse.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021Article
- Machine and deep learning approaches for cancer drug repurposing.Seminars in cancer biology · 2021Review
- Progress in data interoperability to support computational toxicology and chemical safety evaluation.Toxicology and applied pharmacology · 2019Review
- Improving the Utility of the Tox21 Dataset by Deep Metadata Annotations and Constructing Reusable Benchmarked Chemical Reference Signatures.Molecules (Basel, Switzerland) · 2019Article
- A large-scale dataset of in vivo pharmacology assay results.Scientific data · 2018Article
- Modeling Small-Molecule Reactivity Identifies Promiscuous Bioactive Compounds.Journal of chemical information and modeling · 2018Article
- Sustainable data and metadata management at the BD2K-LINCS Data Coordination and Integration Center.Scientific data · 2018Article
- Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data.Nucleic acids research · 2018Article
- ExtendingFrontiers in pharmacology · 2018Article
- Drug target ontology to classify and integrate drug discovery data.Journal of biomedical semantics · 2017Article
- First Proposal of Minimum Information About a Cellular Assay for Regenerative Medicine.Stem cells translational medicine · 2016Article
- High quality, small molecule-activity datasets for kinase research.F1000Research · 2016Article
- Badapple: promiscuity patterns from noisy evidence.Journal of cheminformatics · 2016Article
- Database: A New Article Type in CPT: Pharmacometrics & Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2015Article
- A Data Analysis Pipeline Accounting for Artifacts in Tox21 Quantitative High-Throughput Screening Assays.Journal of biomolecular screening · 2015Article
- Reporting biological assay screening results for maximum impact.Drug discovery today. Technologies · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Huge amounts of high-throughput screening (HTS) data for probe and drug development projects are being generated in the pharmaceutical industry and more recently in the public sector. The resulting experimental datasets are increasingly being disseminated via publically accessible repositories. However, existing repositories lack sufficient metadata to describe the experiments and are often difficult to navigate by non-experts. The lack of standardized descriptions and semantics of biological assays and screening results hinder targeted data retrieval, integration, aggregation, and analyses across different HTS datasets, for example to infer mechanisms of action of small molecule perturbagens. To address these limitations, we created the BioAssay Ontology (BAO). BAO has been developed with a focus on data integration and analysis enabling the classification of assays and screening results by concepts that relate to format, assay design, technology, target, and endpoint. Previously, we reported on the higher-level design of BAO and on the semantic querying capabilities offered by the ontology-indexed triple store of HTS data. Here, we report on our detailed design, annotation pipeline, substantially enlarged annotation knowledgebase, and analysis results. We used BAO to annotate assays from the largest public HTS data repository, PubChem, and demonstrate its utility to categorize and analyze diverse HTS results from numerous experiments. BAO is publically available from the NCBO BioPortal at http://bioportal.bioontology.org/ontologies/1533. BAO provides controlled terminology and uniform scope to report probe and drug discovery screening assays and results. BAO leverages description logic to formalize the domain knowledge and facilitate the semantic integration with diverse other resources. As a consequence, BAO offers the potential to infer new knowledge from a corpus of assay results, for example molecular mechanisms of action of perturbagens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.